What is HS 300490?
HS 300490 is a residual catch-all category within Chapter 30 of the Harmonized System, covering medicaments in measured doses or retail packs that are not classified under more specific subheadings. This includes generic and branded pharmaceuticals — antibiotics, antivirals, cardiovascular drugs, analgesics, and a wide range of over-the-counter and prescription medicines packaged for end-consumer or institutional use.
End markets span healthcare systems, retail pharmacy chains, hospital supply chains, and consumer health segments. Because of its breadth, HS 300490 is frequently used for goods that cross therapeutic categories, making accurate classification critical. Misclassification into or out of this code can trigger duty miscalculation, customs holds, or compliance failures at destination. Always validate the specific formulation against national tariff schedules before shipment.
Top Sourcing Countries for Pharmaceutical Medicaments (Retail Pack)
The US is the dominant import market for HS 300490, drawing significant volumes from multiple origins. Switzerland leads in value share, reflecting its dominance in high-margin branded and biologics formulations — Swiss exports to the US represent the single largest bilateral flow in this code globally. India ranks immediately behind, underpinned by its world-leading generics manufacturing base and cost-competitive API integration; Indian pharma exports to the US have grown structurally over the past decade and now rival Swiss volumes.
Germany and Italy are the next largest European suppliers to the US, both strong in specialty and prescription medicines. China, while a structurally advantaged API producer, plays a materially different role — its finished formulation exports are lower in unit value but high in volume, and its position as a dominant API feedstock supplier to Indian manufacturers adds an indirect layer of supply dependency that procurement teams must map carefully.
Singapore appears as a notable transshipment and regional distribution hub, and its share of US-bound flows warrants scrutiny — not all Singapore-origin shipments represent domestically manufactured product. The US also exports materially to Germany, reflecting the two-way nature of specialty pharmaceutical trade between advanced economies.
Import Duty Rates and Trade Agreements
Duty rates for HS 300490 vary significantly by destination market and should be verified directly with the relevant customs authority before contracting. Many developed markets apply low or zero MFN rates on pharmaceutical products under the WTO Pharmaceutical Agreement (Zero-for-Zero), but this does not apply universally, and some emerging markets maintain tariffs of 5–15% on finished formulations.
Free trade agreements can materially reduce landed costs — for example, EU-origin products may benefit from preferential treatment in markets with active EU FTAs, while Indian exporters targeting certain Asian and African markets can leverage bilateral agreements. Procurement teams should confirm rules-of-origin requirements carefully, particularly given the high transshipment risk profile of this code.
Cost Drivers and Price Outlook
The primary cost driver for HS 300490 is Active Pharmaceutical Ingredient (API) pricing, which is itself influenced by chemical feedstock costs, energy prices, and Chinese regulatory and environmental policy affecting API production. Regulatory compliance costs — GMP certification, pharmacovigilance, registration fees — add a structurally fixed cost layer that disadvantages smaller suppliers and favors scale players.
Patent expiry events are a significant price catalyst: when a branded molecule loses exclusivity, generic entry typically compresses prices materially within 12–24 months. Exchange rate movements, particularly INR/USD and EUR/USD, directly affect export competitiveness from India and Europe respectively. Government price controls in markets such as India, China, and parts of Europe create additional price floor dynamics that procurement teams operating across regions must account for.
Compliance and Sourcing Considerations
HS 300490 carries a high transshipment risk rating. Counterfeit pharmaceuticals frequently exploit routing through intermediary hubs to obscure origin, making supply chain transparency non-negotiable. Importers should require full chain-of-custody documentation, verified certificates of analysis, and GMP certification from the manufacturing site — not just the exporter of record.
Most destination markets require import licenses for pharmaceutical products, and many apply country-of-origin scrutiny that goes beyond standard customs checks. The FDA, EMA, and equivalent national regulators conduct facility inspections and can delist suppliers, creating sudden supply disruption risk. Diversifying across at least two qualified-supplier origins is a standard risk mitigation practice for high-volume buyers in this code.
How to Source Pharmaceutical Medicaments (Retail Pack) Efficiently
Start by mapping your therapeutic category against the specific subheadings within Chapter 30 to confirm HS 300490 is the correct classification — misclassification is common and costly. For generic sourcing, India and China offer materially lower unit costs, but due diligence on GMP status, FDA warning letters, and import alert history is essential before onboarding any new supplier.
- Verify GMP certification at the manufacturing site level, not just the trader
- Check FDA, EMA, and MHRA import alert and inspection databases before contracting
- Map API origin within your supply chain — many Indian generics use Chinese APIs, creating second-tier concentration risk
- Assess transshipment routing and request manufacturer's export declarations for Singapore or other hub-routed shipments
- Confirm import license requirements and registration status in your destination market before placing orders
- Use trade intelligence data to benchmark supplier market share and detect unusual routing patterns
Trade intelligence platforms that aggregate Comtrade flows, customs filings, and compliance records give procurement teams and customs brokers a significant advantage in qualifying suppliers and anticipating regulatory risk before it becomes a shipment problem.
Get a free sourcing intelligence report for HS 300490 at Logitality.com